Biotech Merger Deal
Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Biotech Offerings
Key Points
Bio-Techne brings specific product capabilities, including RNAscope in situ hybridization and the ProteinSimple automated protein detection platform, which Merck KGaA says will strengthen its Discovery Solutions, Advanced Solutions, and Process Solutions offerings after the deal closes.
Bio-Techne's scale and footprint include more than 3,000 employees (about 2,300 in the U.S.), 34 global locations and 15 manufacturing facilities across the U.S., Canada, the U.K., Switzerland and China.
Financial and legal advisory for the deal includes Guggenheim Securities and JPMorgan acting as Merck KGaA’s financial advisers; Goldman Sachs and Goldman Sachs & Co. acting as Financial Adviser for Bio-Techne, with Sullivan & Cromwell advising Bio-Techne on the legal side and Sidley Austin as Bio-Techne’s legal counsel.
Market reaction to the announcement showed a strong premarket run in Bio-Techne shares, with reports of roughly 22% gains in premarket trading.
Merck KGaA has agreed to buy Bio-Techne for $73 per share in cash, valuing the Minneapolis-based life sciences company at $11.3 billion in enterprise value. The deal, announced on June 25, 2026, is Merck KGaA's biggest acquisition since its $17 billion purchase of Sigma-Aldrich in 2015, according to Fierce Pharma.
Bio-Techne shares surged roughly 22% in premarket trading after the news broke, approaching the $73 offer price. The bid carries a 36% premium over Bio-Techne's one-month average trading price. Bio-Techne's board unanimously approved the deal and urged shareholders to vote in favor, according to Yahoo Finance.
Beckmann's First Big Move Reshapes Life Sciences
Kai Beckmann took over as CEO of Merck KGaA on May 1, 2026, replacing Belén Garijo. Less than two months later, he signed off on the company's largest deal in a decade. Beckmann called the acquisition a "milestone towards delivering on our mid- to long-term strategic agenda," according to Fierce Pharma. Bio-Techne CEO Kim Kelderman said the deal is a "testament to the remarkable company our team has built."
The deal is expected to close by late 2026 or early 2027. It requires approval from both shareholders and regulators. Merck will fund the purchase with existing cash and new debt. The company projects the deal will immediately boost its EBITDA margins and add to earnings per share by year three, according to Investors.com.
RNAscope and ProteinSimple Give Merck Key Lab Tools
Bio-Techne brings two standout technologies to the deal. The first is RNAscope, a tool that lets scientists see gene activity inside tissue samples — a fast-growing field called spatial biology. The second is ProteinSimple, a platform that automates protein analysis in labs and cuts down on human error. Both tools slot into Merck KGaA's existing Discovery, Advanced, and Process Solutions divisions, according to Star Tribune.
Bio-Techne posted over $1.2 billion in net sales in fiscal year 2025. The company runs 34 global locations and 15 manufacturing facilities across the U.S., Canada, the U.K., Switzerland, and China. It employs more than 3,000 people, with about 2,300 based in the United States. Analysts at GlobalData said the deal gives Merck tools that span the full chain from lab bench to factory floor.
Activist Investor Pressure Preceded the $11.3B Sale
Bio-Techne had been under pressure from activist investor Ananym Capital Management, which argued the company should sell itself to a larger player to unlock value for shareholders. The $73 per share offer — a 25% premium over Bio-Techne's June 24 closing price of $58.88 — made that case. Board Chairman Robert V. Baumgartner said the price offers "substantial, near-term cash value" for shareholders, according to Star Tribune.
RBC Capital upgraded Bio-Techne immediately after the announcement, citing "M&A confidence" and an attractive valuation relative to sector peers. The life sciences tools sector has seen heavy consolidation in recent years, with Thermo Fisher Scientific and Danaher both snapping up niche technology providers, according to Simply Wall St.
€140 Million in Cost Cuts Targeted by Year Three
Merck KGaA expects to cut about €140 million in annual costs by year three after the deal closes. Those savings will likely come from consolidating real estate and back-office functions across the two companies. Merck employs over 65,000 people globally. After the merger, its Life Science division will generate combined revenue exceeding €10 billion, according to Yahoo Finance.
Guggenheim Securities and JPMorgan advised Merck KGaA on the deal. Goldman Sachs acted as Bio-Techne's exclusive financial adviser. Sullivan & Cromwell and Sidley Austin handled legal work for Bio-Techne. Some investors have flagged potential antitrust scrutiny from the FTC or European Commission, given that both companies hold large shares of the recombinant protein and antibody markets, according to Fierce Pharma.
Sentiment
Mostly PositivePublishers
16
Articles
55
Reach
71
